These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 17635822

  • 1. Lanthanum carbonate--a first line phosphate binder?
    de Freitas D, Donne RL, Hutchison AJ.
    Semin Dial; 2007; 20(4):325-8. PubMed ID: 17635822
    [Abstract] [Full Text] [Related]

  • 2. Lanthanum carbonate as a first-line phosphate binder: the "cons".
    Drüeke TB.
    Semin Dial; 2007; 20(4):329-32. PubMed ID: 17635823
    [Abstract] [Full Text] [Related]

  • 3. Lanthanum: new drug. Hyperphosphataemia in dialysis patients: more potential problems than benefits.
    Prescrire Int; 2007 Apr; 16(88):47-50. PubMed ID: 17458039
    [Abstract] [Full Text] [Related]

  • 4. Emerging drugs for hyperphosphatemia.
    Bellinghieri G, Santoro D, Savica V.
    Expert Opin Emerg Drugs; 2007 Sep; 12(3):355-65. PubMed ID: 17874966
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The role of magnesium binders in chronic kidney disease.
    Spiegel DM.
    Semin Dial; 2007 Sep; 20(4):333-6. PubMed ID: 17635824
    [Abstract] [Full Text] [Related]

  • 11. Optimising the treatment of hyperphosphatemia and vascular calcification in chronic kidney disease.
    Cozzolino M, Brancaccio D.
    Expert Opin Emerg Drugs; 2007 Sep; 12(3):341-3. PubMed ID: 17874964
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A long-term, open-label extension study on the safety of treatment with lanthanum carbonate, a new phosphate binder, in patients receiving hemodialysis.
    Finn WF, Joy MS, LAM-308 Study Group.
    Curr Med Res Opin; 2005 May; 21(5):657-64. PubMed ID: 15969865
    [Abstract] [Full Text] [Related]

  • 15. Control of serum phosphate by oral lanthanum carbonate in patients undergoing haemodialysis and continuous ambulatory peritoneal dialysis in a short-term, placebo-controlled study.
    Al-Baaj F, Speake M, Hutchison AJ.
    Nephrol Dial Transplant; 2005 Apr; 20(4):775-82. PubMed ID: 15703206
    [Abstract] [Full Text] [Related]

  • 16. Lanthanum carbonate for the treatment of hyperphosphataemia in renal failure and dialysis patients.
    Albaaj F, Hutchison AJ.
    Expert Opin Pharmacother; 2005 Feb; 6(2):319-28. PubMed ID: 15757427
    [Abstract] [Full Text] [Related]

  • 17. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate.
    Sprague SM.
    Curr Med Res Opin; 2007 Dec; 23(12):3167-75. PubMed ID: 17991307
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.